Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 14/20 | 0.77 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.64 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.64 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1876218 | 0.93 | MAPK14 (0.80) | MAPK14MAPK9MAPK10MAPK11SMN1; SMN2 | |
| SCHEMBL1878282 | 0.93 | MAPK14 (0.75) | MAPK14MAPK9MAPK10MAPK11LMNA | |
| SCHEMBL1879849 | 0.91 | MAPK14 (0.78) | MAPK14MAPK9MAPK10MAPK11SMN1; SMN2 | |
| SCHEMBL1881470 | 0.90 | MAPK14 (0.76) | MAPK14MAPK9MAPK10MAPK11SMN1; SMN2 | |
| SCHEMBL1881124 | 0.90 | MAPK14 (0.82) | MAPK14MAPK9MAPK10MAPK11SMN1; SMN2 | |
| SCHEMBL1876505 | 0.90 | MAPK14 (0.70) | MAPK14MAPK9MAPK10MAPK11 | |
| SCHEMBL5586277 | 0.90 | MAPK14 (0.65) | MAPK14MAPK9MAPK10MAPK11LMNA | |
| SCHEMBL4343996 | 0.89 | MAPK14 (0.61) | MAPK14MAPK9MAPK10MAPK11SMN1; SMN2 | |
| SCHEMBL1879775 | 0.89 | MAPK14 (0.84) | MAPK14MAPK9MAPK10MAPK11 | |
| SCHEMBL1876445 | 0.88 | MAPK14 (0.73) | MAPK14MAPK9MAPK10MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1832584-B1 | PYRIMIDINYLISOXAZOLE DERIVATIVE | ASKA PHARM CO LTD (JP) | 2011-12-21 | — | — | EP | disclosed |
| US-7939536-B2 | 5-[(2-chlorophenyl)acetylamino]-3-(4-fluorophenyl)-4-(4-pyrimidinyl)isoxazole; p 38MAP kinase inhibitor; tumor necrosis factor, interleukin, or cyclooxygenase-II related diseases; antiinflammatory, anticarcinogenic, antidiabetic agent | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2011-05-10 | — | — | US | disclosed |
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | ASKA PHARMACEUTICAL CO., LTD. (JP) | 2008-05-15 | — | — | US | disclosed |
| EP-1832584-A1 | PYRIMIDINYLISOXAZOL DERIVATIVE | ASKA Pharmaceutical Co., Ltd. (JP) | 2007-09-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114003-A1 | Pyrimidinylisoxazole Derivatives | MAPK3, MAPK7, MAP3K7 | MAPK14 29/4885MAPK9 20/4885MAPK10 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.